Biological Information

Background Information:

SCF Skp2/Cks1 complex is a multi-subunit E3 ubiquitin ligase belonging to the Skp1–Cullin–F-box (SCF) family. It consists of Skp1, Cul1, Rbx1, and the F-box protein Skp2, which functions as the substrate-recognition subunit. Cks1 acts as an adaptor that enhances substrate binding, particularly to phosphorylated targets such as the cyclin-dependent kinase inhibitor p27. The SCF Skp2/Cks1 complex mediates ubiquitin-dependent degradation of key cell-cycle regulators, including p27, p21, and p57, thereby promoting G?/S phase transition and cellular proliferation. Dysregulated Skp2 or Cks1 expression is frequently observed in cancers, correlating with poor prognosis, enhanced proliferation, and resistance to apoptosis.

Target Class:

Ubiquitination-related

Family:

F-box protein

Sub Family:

E3 Ligase

Protein Name:

Skp2

Protein Aliases:

FBXL1; p45skp2 (Skp2)

Accession Number:

NM_005983.2 (Skp2); NM_170679.2 (Skp1); NM_003592.2 (Cul1); NM_014248.2 (Rbx1); NM_001826.2 (Cks1)

UniProt Number:

Q13309 (Skp2)

Gene Name:

SKP2 (Skp2)

Gene ID:

6502 (Skp2)

Gene Aliases:

p45; FBL1; FLB1; FBXL1 (Skp2)

Target Species:

Human

Usage

Product Type:

Enzymes

Application:

Drug Discovery & Development

Storage Conditions:

1 year at -70°C

Usage disclaimer:

These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Assay Information

Assay Type:

Enzymatic

Assay Measures:

ECL

Bioassay Data

Trademark Statement:

For Research Use Only

Clinical Relevance

Therapeutic Area:

Oncology